Rad23A: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: RAD23A

NCBI ID: G5886

RAD23A

Rad23A: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Rad23A (MGC111083) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development and progression of various diseases, including cancer. In this article , we will discuss the research on Rad23A and its potential as a drug target and biomarker.

Structure and Function

Rad23A is a small non-coding RNA molecule that was identified using RNA-based screening techniques. It has a unique structure that consists of a 19-nt stem-loop and a 31-nt open-ended tail. The stem-loop region is the most conserved part of the molecule and is involved in the formation of a stem-loop-like structure. The open-ended tail region is the least conserved and is involved in the formation of a loop that is similar to the stem-loop.

Rad23A is involved in the regulation of the cell cycle at various stages, including G1, S, and G2/M. It is a negative regulator of the G1 phase and a positive regulator of the S and G2/M phases. This means that it promotes the stay in G1 and S phases and inhibits the transition from G2/M to S.

Rad23A is also involved in the regulation of apoptosis, which is the process of cell death. It has been shown to play a role in the regulation of apoptosis in various cell types, including cancer cells.

Potential Drug Target

Rad23A has been identified as a potential drug target due to its involvement in the regulation of the cell cycle and apoptosis. Many drugs that are currently in use target the cell cycle or apoptosis, so it is possible that Rad23A could be a useful drug target for cancer treatment.

One way to target Rad23A is through inhibition of its activity as a negative regulator of the cell cycle. This could be done through inhibition of the activity of the protein kinase kinase A1 (PKA), which is a target of Rad23A.

Another way to target Rad23A is through inhibition of its activity as a positive regulator of apoptosis. This could be done through inhibition of the activity of the protein Bax, which is a target of Rad23A in cancer cells.

Rad23A as a Biomarker

Rad23A has also been identified as a potential biomarker for various diseases, including cancer. Its involvement in the regulation of the cell cycle and apoptosis makes it an attractive candidate for use as a biomarker in these diseases.

One of the main advantages of Rad23A as a biomarker is its ability to be easily measured and detected. This is because it is a non-coding RNA molecule, which means that it can be easily isolated and detected using techniques such as RNA sequencing.

Rad23A has been shown to be elevated in the blood and other body fluids of patients with various diseases, including cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

In conclusion, Rad23A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and involvement in the regulation of the cell cycle and apoptosis make it an attractive candidate for drug development. Further research is needed to fully understand its potential as a drug target and biomarker.

Protein Name: RAD23 Homolog A, Nucleotide Excision Repair Protein

Functions: Multiubiquitin chain receptor involved in modulation of proteasomal degradation. Binds to 'Lys-48'-linked polyubiquitin chains in a length-dependent manner and with a lower affinity to 'Lys-63'-linked polyubiquitin chains. Proposed to be capable to bind simultaneously to the 26S proteasome and to polyubiquitinated substrates and to deliver ubiquitinated proteins to the proteasome

The "RAD23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets